Scott L. Carter, Priscilla K. Brastianos, Ryan J. Sullivan, Mario L. Suvà, Arlene H. Sharpe, Michael A. Davies, Benjamin Izar, Genevieve Marie Boland, Daniel P. Cahill, Bob Carter, William T. Curry, Brian V. Nahed, Elizabeth Gerstner, Nancy Wang, Matthew Frosch, Maria Martinez-Lage, McKenzie Shaw, Christine Hebert, Dennie T. Frederick, Brian C. Miller, Kristen E. Pauken, Osmaan Shahid, Michael White, Husain Danish, Swaminathan Kumar, Aarushi Jain, Megha Subramanian, Alexander Kaplan, Brian Shaw, Mia Bertalan, Corey M. Gill, Benjamin M. Kuter, Robert H. Klein, Andrew W. Navia, Joana L. Mora, Juliana M. Larson, Ashish Dahal, Magali de Sauvage, Albert E. Kim, Matthew R. Strickland, Matt Lastrapes, Naema Nayyar, Jackson H. Stocking, Samuel C. Markson, and Christopher Alvarez-Breckenridge
Melanoma-derived brain metastases (MBM) represent an unmet clinical need because central nervous system progression is frequently an end stage of the disease. Immune checkpoint inhibitors (ICI) provide a clinical opportunity against MBM; however, the MBM tumor microenvironment (TME) has not been fully elucidated in the context of ICI. To dissect unique elements of the MBM TME and correlates of MBM response to ICI, we collected 32 fresh MBM and performed single-cell RNA sequencing of the MBM TME and T-cell receptor clonotyping on T cells from MBM and matched blood and extracranial lesions. We observed myeloid phenotypic heterogeneity in the MBM TME, most notably multiple distinct neutrophil states, including an IL8-expressing population that correlated with malignant cell epithelial-to-mesenchymal transition. In addition, we observed significant relationships between intracranial T-cell phenotypes and the distribution of T-cell clonotypes intracranially and peripherally. We found that the phenotype, clonotype, and overall number of MBM-infiltrating T cells were associated with response to ICI, suggesting that ICI-responsive MBMs interact with peripheral blood in a manner similar to extracranial lesions. These data identify unique features of the MBM TME that may represent potential targets to improve clinical outcomes for patients with MBM.